Skip to main content

Table 1 Clinical and laboratory features of the 20 patients with idiopathic inflammatory myositis

From: Voluntary activation failure is detectable in some myositis patients with persisting quadriceps femoris weakness: an observational study

Patient Age/gender IIM Subtype IIM duration (yr) Treatment CK IU/l (24–170) CRP IU/l (0–10) MMT QF EMG MRI Disease activity
1 35/M PM/MCTD 8 P 5, Aza 60 9 5 ND ND Inactive
2 34/M DM 0.5 P 30, SELAM 95 12 5 + + Active -
3 46/M PM/CTD 6 P 20, MMF 109 40 5 ND ND Inactive
4 62/F PM 1 P 7, SELAM 97 14 5 + ND Active -
5 59/F PM 8 - 48 43 5 ND ND Inactive
6 62/F DM 6 - 129 10 4+ ND ND Inactive
7 68/F PM 1 Mtx 653 10 5 + ND Active -
8 40/F DM 6 P 30, CyA, Mtx 486 11 4+ ND ND Active -
9 47/M PM 12 P 10, Mtx 3,500 2 4- + + Active +
10 67/F PM/MCTD 10 P 10, Mtx 170 2 4+ ND + Active
11 58/F PM/UCTD 1 P 7.5, SELAM 181 2 5 ND ND Active
12 50/F PM 0.5 P 10, CyA, Aza 53 2 4 + ND Inactive
13 59/F DM 7 P 7.5, Aza 144 6 5 ND ND Active -
14 66/F PM 1 P 10, SELAM 159 2 4+ ND ND Active
15 43/F PM/MCTD 3 P 30, CyA, Aza 305 1 4 ND ND Active -
16 41/F PM 8 P 15 282 7 5 ND + Active -
17 * 49/F PM 12 P 7.5 296 22 3- ND ND Active
18 46/F PM 6 P 30, MMF 3,331 31 3+ ND ND Active +
19 * 68/F PM/MCTD 5 P 7, Mtx 83 8 4 ND ND Inactive
20 50/M DM 10 Mtx 39 2 4+ ND - Inactive
  1. CRP and CPK levels were current at the time of recruitment and are those used during disease activity and damage assessments. Extended MMT score is that for dominant QF. If EMG or MRI of QF had been performed within the previous 6 months, - or + indicates the absence or presence of inflammation, respectively. *Patients 17 and 19 had had muscle biopsies within the previous 6 months, and both showed end-stage disease with severe muscle atrophy and fatty and fibrosis replacement. Aza, azathioprine; CK, creatinine kinase; CRP, C-reactive protein; CyA, cyclosporin A; DM, dermatomyositis; EMG, electromyography; IIM, idiopathic inflammatory myositis; IU/l, international units per litre; MCTD, mixed connective tissue disease; MMF, mycophenolate mofetil; MMT, manual muscle testing; MRI, magnetic resonance imaging; Mtx, methotrexate; ND, (test) not done; P, prednisolone (daily dose, mg); PM, polymyositis; QF, quadriceps femoris; SELAM, patient participating in "SEcond Line Agents in Myositis" study, so on prednisolone plus Mtx or placebo and CyA or placebo; UCTD, undifferentiated connective tissue disease.
\